New hope for Hard-to-Treat prostate cancer: targeted radiation plus chemo
NCT ID NCT07316686
First seen Jan 09, 2026 · Last updated May 08, 2026 · Updated 21 times
Summary
This early-phase study tests a combination of chemotherapy (docetaxel) and a targeted radioactive drug (177Lu-PSMA) in 18 men with advanced prostate cancer that has stopped responding to hormone therapy. The main goal is to find the safest dose of docetaxel when given with the radioactive drug. Participants will receive both treatments along with standard hormone therapy. This is not a cure, but aims to better control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER (ADENOCARCINOMA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Instituto do Câncer do Estado de São Paulo - ICESP
São Paulo, São Paulo, 01246000, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.